TG Therapeutics (TGTX) Year-over-year earnings per share growth for the last twelve months

Public company logo of TG Therapeutics Corp (TGTX)

TG Therapeutics, Inc. (TGTX) is aggressively capturing the multiple sclerosis therapy niche through the high efficacy of its solutions. The current quarterly EPS growth rate on the GURU.Markets system chart confirms this success, where -85.70 characterizes this valuation parameter. Explosive earnings are driven by the low synthesis cost of Briumvi, while sales stability is guaranteed by the drug's critical importance regardless of economic cycles.

TG Therapeutics Inc (TGTX) - Year-over-year earnings per share growth for the last 12 months from 07/04/2022 to 11/18/2026

Metric breakdowns and analytics for TG Therapeutics (TGTX)

- market value and analyst target forecast:
Summary company analytics:TG Therapeutics, TGTX
Flagship merchandise of tgtherapeutics.com

Quarterly EPS growth measures the dynamics of net income per share, filtering out one-time market noise to assess the actual efficiency of the business. This metric captures the company's ability to generate a sustainable cash flow. For TG Therapeutics, Inc. (TGTX), this growth confirms the financial returns from the implementation of ethical biotechnologies and ESG standards. Analyzing the relative change in EPS over the quarter allows for the verification of the price momentum's validity. A positive trend reduces the risk of overpayment, confirming the asset's fundamental stability.

Competitor analysis for TG Therapeutics, Inc.

arcellx.com (ACLX) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Disc Medicine Pharma (IRON)|Year-over-year earnings per share growth for the last twelve months Syndax Pharmaceuticals Inc|Earnings per share growth in annualized terms for the last twelve months Kura Oncology, Inc. KURA|Quarterly EPS earnings growth ADCT|Foghorn Therapeutics Inc. - Year-over-year earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months vorbio.com VOR|NKTX: Year-over-year earnings per share growth for the last 12 months|COEP - Year-over-year earnings per share growth for the last twelve months|Actinium Pharmaceuticals, Inc. (ATNM) - Year-over-year net earnings per share growth for the last 12 months|ESLA (Estrella Immunopharma) - Year-over-year net earnings per share growth for the last 12 months|CASI - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Marker Bio|Quarterly EPS earnings growth IN8bio, Inc.|Year-over-year earnings per share growth for the last twelve months Eterna Therapeutics Inc (ERNA)|Year-over-year net earnings per share change for the last twelve months gtbiopharma.com|Quarterly EPS earnings growth APTO (Aptose Biosciences)|Quarterly EPS earnings growth Bio-Path BPTH|MEI Pharma Inc - Quarterly EPS earnings growth|VINC (Vincerx Pharma Inc.) - Year-over-year earnings per share growth for the last 12 months